Androgen excess contributes to altered growth hormone/insulin-like growth factor-1 axis in nonobese women with polycystic ovary syndrome

Wu, Xiaoke; Sallinen, Kirsimarja; Shan-ying, Zhou; Su, Yan-Hua; Pöllänen, Pasi; Erkkola, Risto

doi:10.1016/s0015-0282(99)00634-2

Cited by 22 publications

(9 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, serum IGF-I concentration was increased in women with PCOS compared with controls but was not related to sympathetic nerve traffic. The elevated serum IGF-I levels in the present study are in line with a previous observation in lean PCOS women, whereas obese PCOS women exhibited normal levels (32,53), indicating that it is the androgen excess that contributes to the elevated IGF-I levels.…”

Section: Discussionsupporting

confidence: 92%

“…Nonetheless, PCOS is associated with hyperandrogenemia, hyperinsulinemia, and insulin resistance, as well as abdominal obesity and cardiovascular disease, all factors hypothesized to be associated with increased activity of the sympathetic nervous system (8). Furthermore, PCOS is associated with disturbances in the somatotropic axis, i.e., the growth hormone (GH)/insulin growth factor (IGF)-I axis (53), which plays a central role in the regulation of central sympathetic outflow (42)(43)(44).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Is polycystic ovary syndrome associated with high sympathetic nerve activity and size at birth?

Sverrisdóttir

Mogren²,

Kataoka³

et al. 2008

American Journal of Physiology-Endocrinology and Metabolism

181

162

View full text Add to dashboard Cite

Sverrisdóttir YB, Mogren T, Kataoka J, Janson PO, StenerVictorin E. Is polycystic ovary syndrome associated with high sympathetic nerve activity and size at birth? Am J Physiol Endocrinol Metab 294: E576-E581, 2008. First published January 15, 2008 doi:10.1152/ajpendo.00725.2007.-Polycystic ovary syndrome (PCOS) is a common endocrine and metabolic disturbance among women of reproductive age and is proposed to be linked with size at birth and increased prevalence of cardiovascular disease. A disturbance in the sympathetic nervous system may contribute to the etiology of PCOS. This study evaluates sympathetic outflow in PCOS and its relation to size at birth. Directly recorded sympathetic nerve activity to the muscle vascular bed (MSNA) was obtained in 20 women with PCOS and in 18 matched controls. Ovarian ultrasonographic evaluation, biometric, hormonal, and biochemical parameters were measured, and birth data were collected. Women with PCOS had increased MSNA (30 Ϯ 8 vs. 20 Ϯ 7 burst frequency, P Ͻ 0.0005) compared with controls. MSNA was positively related to testosterone (r ϭ 0.63, P Ͻ 0.005) and cholesterol (r ϭ 0.55, P ϭ 0.01) levels in PCOS, which, in turn, were not related to each other. Testosterone level was a stronger predictor of MSNA than cholesterol. Birth size did not differ between the study groups. This is the first study to directly address sympathetic nerve activity in women with PCOS and shows that PCOS is associated with high MSNA. Testosterone and cholesterol levels are identified as independent predictors of MSNA in PCOS, although testosterone has a stronger impact. The increased MSNA in PCOS may contribute to the increased cardiovascular risk and etiology of the condition. In this study, PCOS was not related to size at birth. birth weight; testosterone; insulin resistance; metabolic syndrome; cardiovascular disease; autonomic nervous system POLYCYSTIC OVARY SYNDROME (PCOS), the most common female endocrine disorder, is a complex and heterogenic disease with unknown etiology (28). PCOS is characterized by reproductive disturbances including chronic anovulation, hyperandrogenism, and polycystic ovaries (28). Although ovarian hyperandrogenemia, which is the most consistent endocrine feature of PCOS, probably plays a key role in its etiology (1, 12), hyperinsulinemia and insulin resistance, as well as abdominal obesity, are also thought to be important etiological factors in PCOS (2, 6). Women with PCOS often develop hypertension, which may involve an increased risk of developing other cardiovascular diseases (4), and seem to have increased psychological distress and a decreased quality of life (17).

show abstract

Section: Discussionsupporting

confidence: 92%

mentioning

confidence: 99%

Is polycystic ovary syndrome associated with high sympathetic nerve activity and size at birth?

Sverrisdóttir

Mogren²,

Kataoka³

et al. 2008

American Journal of Physiology-Endocrinology and Metabolism

181

162

View full text Add to dashboard Cite

show abstract

“…Both are further affected by some neurotransmitters like dopamine and opioids (Muller et al 1999). In PCOS, the dopaminergic activity is found to be reduced (Paradisi et al 1988) and thus can affect the GH level (Wu et al 2000). The GH exerts most of its function through peripheral IGF-1 (Adashi et al 1985, Katz et al 1993, which in turn participates in the negative feedback regulation of GH (Katz et al 1993, Muller et al 1999.…”

Section: Pcos and Growth Hormonementioning

confidence: 99%

“…The GH exerts most of its function through peripheral IGF-1 (Adashi et al 1985, Katz et al 1993, which in turn participates in the negative feedback regulation of GH (Katz et al 1993, Muller et al 1999. The hyperinsulinemia seen in PCOS can increase free IGF-1 production which in turn can decrease GH release through increased hypothalamic somatostatin secretion (Wu et al 2000). Somatostatin release can also be directly stimulated by hyperandrogenemia as testosterone can increase somatostatin secretion.…”

Section: Pcos and Growth Hormonementioning

confidence: 99%

Hormonal alterations in PCOS and its influence on bone metabolism

Krishnan¹,

Muthusami²

2017

Journal of Endocrinology

127

View full text Add to dashboard Cite

According to the World Health Organization (WHO) polycystic ovary syndrome (PCOS) occurs in 4-8% of women worldwide. The prevalence of PCOS in Indian adolescents is 12.2% according to the Indian Council of Medical Research (ICMR). The National Institute of Health has documented that it affects approximately 5 million women of reproductive age in the United States. Hormonal imbalance is the characteristic of many women with polycystic ovarian syndrome (PCOS). The influence of various endocrine changes in PCOS women and their relevance to bone remains to be documented. Hormones, which include gonadotrophin-releasing hormone (GnRH), insulin, the leutinizing/follicle-stimulating hormone (LH/FSH) ratio, androgens, estrogens, growth hormones (GH), cortisol, parathyroid hormone (PTH) and calcitonin are disturbed in PCOS women. These hormones influence bone metabolism in human subjects directly as well as indirectly. The imbalance in these hormones results in increased prevalence of osteoporosis in PCOS women. Limited evidence suggests that the drugs taken during the treatment of PCOS increase the risk of bone fracture in PCOS patients through endocrine disruption. This review is aimed at the identification of the relationship between bone mineral density and hormonal changes in PCOS subjects and identifies potential areas to study bone-related disorders in PCOS women.

show abstract

“…Altered FSHR function caused by a number of FSHR genetic variants induces arrest of follicle development, resulting in functional changes, such as primary amenorrhea, hypoplastic ovary, and high FSH serum levels. Altered FSH/LH ratio was linked with insulin resistance [15], and with altered production of and responsiveness to sex hormones, in particular testosterone [16].…”

Section: Introductionmentioning

confidence: 99%

Leutinizing hormone/choriogonadotropin receptor and follicle stimulating hormone receptor gene variants in polycystic ovary syndrome

Almawi

Hubail

Arekat

et al. 2015

J Assist Reprod Genet

View full text Add to dashboard Cite

Purpose Previous studies identified follicle-stimulating hormone receptor (FSHR) and luteinizing hormone/ choriogonadotropin receptor (LHCGR) genes as polycystic ovary syndrome (PCOS) susceptibility loci, which was dependent on the racial/ethnic background of studied population. We investigated the association of genetic variants in FSHR and LHCGR with PCOS in Bahraini Arab women. Methods A retrospective case-control study, involving 203 women with PCOS, and 211 age-and ethnically-matched control women. FSHR and LHCGR genotyping was done by allelic exclusion method (real-time PCR).Results Significantly lower frequencies of heterozygous LHCGR rs7371084 and FSHR rs11692782 genotype carriers were seen between women with PCOS vs. controls, and increased frequency of heterozygous homozygous LHCGR rs4953616 genotype carriers were detected between women with PCOS compared to control women. Limited linkage disequilibrium was noted among LHCGR and FSHR SNPs, and 2 blocks were constructed: the first (Block 1) spanning 61 kb contained the six tested LHCGR SNPs, and the second (Block 2) spanning 298 kb contained four of the five tested FSHR SNPs. Higher frequency of LHCGR GTCAAG haplotype was seen in women with PCOS compared to controls; the frequencies of the remaining LHCGR haplotypes, and all FSHR haplotypes were similar between cases and controls. Conclusion This is the first study to confirm the association of novel LHCGR (rs7371084, rs4953616) and FSHR (rs11692782) SNPs with PCOS. The differential association of LHCGR and FSHR variants with PCOS confirms the racial/ ethnic contribution to their association with PCOS.

show abstract

Androgen excess contributes to altered growth hormone/insulin-like growth factor-1 axis in nonobese women with polycystic ovary syndrome

Cited by 22 publications

References 22 publications

Is polycystic ovary syndrome associated with high sympathetic nerve activity and size at birth?

Is polycystic ovary syndrome associated with high sympathetic nerve activity and size at birth?

Hormonal alterations in PCOS and its influence on bone metabolism

Leutinizing hormone/choriogonadotropin receptor and follicle stimulating hormone receptor gene variants in polycystic ovary syndrome

Contact Info

Product

Resources

About